If continued anti-VEGF treatment can lead to reductions in vision due to an increase in the size of the RPE atrophy, then continued anti-VEGF treatment is not necessarily beneficial for some patients, even if it decreases the risk of reductions in vision due to exudations. The gene discussed is VEGFA; the disease is Atrophy.